Logo image of CING

CINGULATE INC (CING) Stock Fundamental Analysis

NASDAQ:CING - Nasdaq - US17248W3034 - Common Stock - Currency: USD

4.27  +0.04 (+0.95%)

After market: 4.39 +0.12 (+2.81%)

Fundamental Rating

2

Overall CING gets a fundamental rating of 2 out of 10. We evaluated CING against 194 industry peers in the Pharmaceuticals industry. The financial health of CING is average, but there are quite some concerns on its profitability. CING has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CING has reported negative net income.
In the past year CING has reported a negative cash flow from operations.
In the past 5 years CING always reported negative net income.
CING had a negative operating cash flow in each of the past 5 years.
CING Yearly Net Income VS EBIT VS OCF VS FCFCING Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -120.39%, CING is doing worse than 80.54% of the companies in the same industry.
CING's Return On Equity of -135.81% is on the low side compared to the rest of the industry. CING is outperformed by 63.78% of its industry peers.
Industry RankSector Rank
ROA -120.39%
ROE -135.81%
ROIC N/A
ROA(3y)-306.5%
ROA(5y)-252.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CING Yearly ROA, ROE, ROICCING Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

CING does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CING Yearly Profit, Operating, Gross MarginsCING Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, CING has less shares outstanding
The debt/assets ratio for CING is higher compared to a year ago.
CING Yearly Shares OutstandingCING Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M
CING Yearly Total Debt VS Total AssetsCING Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -8.30, we must say that CING is in the distress zone and has some risk of bankruptcy.
CING has a Altman-Z score of -8.30. This is in the lower half of the industry: CING underperforms 70.81% of its industry peers.
CING has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.3
ROIC/WACCN/A
WACCN/A
CING Yearly LT Debt VS Equity VS FCFCING Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

CING has a Current Ratio of 7.35. This indicates that CING is financially healthy and has no problem in meeting its short term obligations.
CING's Current ratio of 7.35 is fine compared to the rest of the industry. CING outperforms 76.22% of its industry peers.
CING has a Quick Ratio of 7.35. This indicates that CING is financially healthy and has no problem in meeting its short term obligations.
CING's Quick ratio of 7.35 is fine compared to the rest of the industry. CING outperforms 77.30% of its industry peers.
Industry RankSector Rank
Current Ratio 7.35
Quick Ratio 7.35
CING Yearly Current Assets VS Current LiabilitesCING Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

CING shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.80%, which is quite impressive.
EPS 1Y (TTM)72.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CING is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.98% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.9%
EPS Next 2Y40.99%
EPS Next 3Y25.91%
EPS Next 5Y14.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CING Yearly Revenue VS EstimatesCING Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M
CING Yearly EPS VS EstimatesCING Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CING. In the last year negative earnings were reported.
Also next year CING is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CING Price Earnings VS Forward Price EarningsCING Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CING Per share dataCING EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as CING's earnings are expected to grow with 25.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.99%
EPS Next 3Y25.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CING!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CINGULATE INC

NASDAQ:CING (2/21/2025, 8:09:13 PM)

After market: 4.39 +0.12 (+2.81%)

4.27

+0.04 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners2.84%
Inst Owner Change81.04%
Ins Owners0.13%
Ins Owner Change0%
Market Cap13.71M
Analysts82
Price Target36.11 (745.67%)
Short Float %3.44%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.5%
Min EPS beat(2)4.92%
Max EPS beat(2)24.09%
EPS beat(4)3
Avg EPS beat(4)6%
Min EPS beat(4)-54.52%
Max EPS beat(4)49.51%
EPS beat(8)4
Avg EPS beat(8)-2.81%
EPS beat(12)7
Avg EPS beat(12)-3.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-41.24%
PT rev (3m)-55.93%
EPS NQ rev (1m)18.84%
EPS NQ rev (3m)38.47%
EPS NY rev (1m)-26.31%
EPS NY rev (3m)6.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-106.42
EYN/A
EPS(NY)-4.66
Fwd EYN/A
FCF(TTM)-5.34
FCFYN/A
OCF(TTM)-5.28
OCFYN/A
SpS0
BVpS3.75
TBVpS3.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -120.39%
ROE -135.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-306.5%
ROA(5y)-252.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.35
Quick Ratio 7.35
Altman-Z -8.3
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.66%
Cap/Depr(5y)163.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.46%
EPS Next Y96.9%
EPS Next 2Y40.99%
EPS Next 3Y25.91%
EPS Next 5Y14.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.9%
OCF growth 3YN/A
OCF growth 5YN/A